Aegis Capital Starts Achaogen (AKAO) at Buy
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Aegis Capital initiated coverage on Achaogen (NASDAQ: AKAO) with a Buy rating and a price target of $10.00.
Shares of Achaogen closed at $4.49 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guggenheim Starts Achaogen (AKAO) at Buy; Positive on Plazomicin Approval, Seen as Takeout Target
- Susquehanna Starts Ally Financial (ALLY) at Positive
- Morgan Stanley Starts Liberty Global (LBTYA) at Equalweight